Agios Pharmaceuticals' Pyrukynd Revenue Reaches $20M in Q4 2025

By Chris Stiles • Thursday, February 12 12:51 • Permanent Link

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has reported its financial results for the fourth quarter and full year 2025. The company's net revenues for Pyrukynd® (mitapivat) were $20.0 million in the fourth quarter and $54.0 million for the full year. In the fourth quarter of 2025, U.S. net revenue for Pyrukynd was $16.0 million, representing a 49% increase from the fourth quarter of 2024. Ex-U.S. net revenue for Pyrukynd was $4.0 million in the fourth quarter of 2025.

The company's net loss for the fourth quarter of 2025 was $108.0 million, compared to a net loss of $96.5 million for the same period in 2024. Net product revenue from U.S. sales of Pyrukynd for the fourth quarter of 2025 increased to $16.0 million from $10.7 million in the fourth quarter of 2024. Net product revenue from ex-U.S. sales of Pyrukynd for the fourth quarter of 2025 was $4.0 million.

Additionally, the company's cash, cash equivalents, and marketable securities totaled $1.2 billion as of December 31, 2025, down from $1.5 billion as of December 31, 2024.

In terms of research and development (R&D) expenses, Agios reported $88.1 million for the fourth quarter of 2025, compared to $82.8 million for the same period in 2024. Selling, general and administrative (SG&A) expenses were $51.6 million for the fourth quarter of 2025, remaining flat compared to the fourth quarter of 2024.

Looking ahead, Agios expects its cash, cash equivalents, and marketable securities, along with anticipated product revenue and interest income, to provide the financial independence needed to execute the U.S. commercial launch of Aqvesme in thalassemia, prepare for the potential U.S. commercial launch of Mitapivat in sickle cell disease, advance existing clinical programs, and opportunistically expand its pipeline through both internally and externally discovered assets.

Agios Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases. Following these announcements, the company's shares moved -2.19%, and are now trading at a price of $27.19. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.